Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Scope Fluidics Spolka Akcyjna's average EBITDA Per Share Growth Rate was -144.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Scope Fluidics Spolka Akcyjna was -14.30% per year. The lowest was -45.10% per year. And the median was -33.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Scope Fluidics Spolka Akcyjna 3-Year EBITDA Growth Rate Related Terms
WAR:SCP vs TMO, DHR, NTRA: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Scope Fluidics Spolka Akcyjna's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scope Fluidics Spolka Akcyjna 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Scope Fluidics Spolka Akcyjna's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Scope Fluidics Spolka Akcyjna's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Scope Fluidics Spolka Akcyjna (WAR:SCP) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Scope Fluidics Spolka Akcyjna and its competitors. According to the industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #999999 out of 167 companies in the Medical Diagnostics & Research industry.
Is Scope Fluidics Spolka Akcyjna's 3-Year EBITDA Growth Rate too high?
Scope Fluidics Spolka Akcyjna's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Scope Fluidics Spolka Akcyjna ranks #999999 out of 167 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Scope Fluidics Spolka Akcyjna has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scope Fluidics Spolka Akcyjna's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #999999 out of 167 companies for 3-Year EBITDA Growth Rate. This places Scope Fluidics Spolka Akcyjna in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 10.60, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Scope Fluidics Spolka Akcyjna and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 10.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scope Fluidics Spolka Akcyjna's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scope Fluidics Spolka Akcyjna stock overvalued right now?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna (WAR:SCP) is currently considered Fairly Valued. The stock's GF Value™ is zł124.31, compared to a current price of zł129.00 — trading 3.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Scope Fluidics Spolka Akcyjna's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Scope Fluidics Spolka Akcyjna (WAR:SCP), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scope Fluidics Spolka Akcyjna (WAR:SCP) Overvalued in 2026?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna stock appears to be overvalued.
The current stock price of zł129.00 is trading 3.8% above its estimated GF Value™ of zł124.31.
GuruFocus considers Scope Fluidics Spolka Akcyjna to be Fairly Valued.
Key valuation signals for WAR:SCP:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: zł124.31 vs. price of zł129.00 (3.8% above fair value)
No single metric tells the full story. See the WAR:SCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services.
49GF Score
Get the complete analysis for WAR:SCP
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCP has been successfully added to your 
